Dr. Pop-Busui has published 200 peer-reviewed manuscripts and book chapters, and received awards from the Fulbright Foundation, the American Diabetes Association (ADA), and the University of Michigan. She has been an elected member of the Clinical Practice Committee of the ADA, the Chair of the American Diabetes Association Scientific Research Review Clinical, and Chair of the ADA Diabetes & Cardiovascular Disease Interest Group. She is also one of the principal investigators in the recently established NIDDK Diabetes Foot Consortium. She has contributed her research efforts and leadership to some of the most important national and international diabetes clinical trials to date including: the NHLBI-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the following NIDDK-funded trials: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications, A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in Type 1 Diabetes (“PERL), “Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE), Bypass Angioplasty Revascularization Diabetes 2 (BARI- 2D), Targeting Inflammation with Salsalate for Type 2 Diabetes (TINSAL T2D), and many others funded by Foundations and Industry such as the Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE), Wireless Innovation for Seniors with Diabetes Mellitus (WISDM), or REPLACE-BG. In addition, she designed and leads several investigator-initiated studies funded by NIDDK and Pharma to unveil disease modifying agents for diabetic neuropathy and other diabetes complications.